To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Summary
What This Bill Does
The bill requires risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone under the Federal Food, Drug, and Cosmetic Act, requires federal tort liability for telehealth providers, pharmacies, and others who import or transport mifepristone in violation of federal law, and requires ban on importation of mifepristone into the United States, including by mail. It relies on compliance mandates, product standards, liability protections, and trade restrictions. The main policy areas are Healthcare and Finance.
Who Benefits and How
Patients who experience adverse effects from mifepristone could face fewer barriers, Trial lawyers and plaintiff attorneys could gain revenue opportunities, and Domestic mifepristone manufacturers (Danco Laboratories) could face fewer barriers.
Who Bears the Burden and How
Telehealth abortion providers could face increased risk, International mifepristone manufacturers and suppliers could lose revenue opportunities, and Online pharmacies shipping mifepristone from abroad could face higher barriers.
Key Provisions
- Requires risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone under the Federal Food, Drug, and Cosmetic Act.
- Requires federal tort liability for telehealth providers, pharmacies, and others who import or transport mifepristone in violation of federal law.
- Requires ban on importation of mifepristone into the United States, including by mail.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone under the Federal Food, Drug, and Cosmetic Act, requires federal tort liability for telehealth providers, pharmacies, and others who import or transport mifepristone in violation of federal law, and requires ban on importation of mifepristone into the United States, including by mail.
Key Policy Areas
Healthcare, Finance
Primary Purpose
The bill requires risk Evaluation and Mitigation Strategy (REMS) requirements for mifepristone under the Federal Food, Drug, and Cosmetic Act, requires federal tort liability for telehealth providers, pharmacies, and others who import or transport mifepristone in violation of federal law, and requires ban on importation of mifepristone into the United States, including by mail.
Policy Domains
Whole bill
Identified Gains
- Patients who experience adverse effects from mifepristone
- Trial lawyers and plaintiff attorneys
- Domestic mifepristone manufacturers (Danco Laboratories)
Identified Costs
- Telehealth abortion providers
- International mifepristone manufacturers and suppliers
- Online pharmacies shipping mifepristone from abroad
- Mifepristone manufacturers (Danco Laboratories, GenBioPro)
- Patients seeking medication abortion
Sponsors
Legislative Progress
IntroducedMrs. Miller of Illinois (for herself, Mr. Moore of Alabama, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Online and mail-order pharmacies, Online and mail-order pharmacies dispensing mifepristone, Online pharmacies shipping mifepristone from abroad
Domestic mifepristone manufacturers (Danco Laboratories), International mifepristone manufacturers and suppliers, Mifepristone manufacturers (Danco Laboratories, GenBioPro)
Positive-direction: Domestic mifepristone manufacturers (Danco Laboratories)
Negative-direction: International mifepristone manufacturers and suppliers, Mifepristone manufacturers (Danco Laboratories, GenBioPro)
Patients seeking imported mifepristone, Patients seeking medication abortion, Patients who experience adverse effects from mifepristone
Positive-direction: Patients who experience adverse effects from mifepristone
Negative-direction: Patients seeking imported mifepristone, Patients seeking medication abortion
Customs and Border Protection, FDA regulatory authority
In-person prescribing physicians and clinics
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology